In current CLL practice, a positive MRD result after fixed-duration therapy does not trigger a change in treatment, such as extending therapy. It serves as a prognostic tool to inform the patient and physician about the likely duration of remission and the need for closer monitoring.
The AMPLIFY regimen (acalabrutinib + venetoclax) has a built-in safety advantage. The initial two cycles of acalabrutinib monotherapy effectively debulk the disease, significantly reducing the risk of tumor lysis syndrome (TLS) when the potent BCL-2 inhibitor venetoclax is introduced later.
Subtle differences between second-generation BTK inhibitors like zanubrutinib and acalabrutinib lie in their pharmacokinetics. Zanubrutinib's ability to maintain drug concentration above the IC50 for the entire dosing interval may provide a theoretical advantage in highly proliferative disease by inhibiting newly synthesized BTK.
When a CLL patient progresses on a BTK inhibitor, experts may overlap it with venetoclax for a month or two. This practical, off-label approach leverages potential synergism and provides disease control while the venetoclax dose is being ramped up, before discontinuing the failing BTK inhibitor.
In CLL, Progression-Free Survival (PFS) is a misleading metric for clinical benefit. Time-To-Next-Treatment (TTNT) is often much longer because patients can have biochemical or radiological progression by IWCLL criteria but remain asymptomatic and clinically well, delaying the need for a new therapy.
Using the non-covalent BTK inhibitor pirtobrutinib in the frontline setting poses a strategic risk. It can induce resistance mutations (e.g., T474I) that confer cross-resistance to both covalent and non-covalent BTK inhibitors, potentially eliminating an entire class of drugs for future use.
Higher death rates observed in the triplet therapy arms of recent CLL trials (e.g., AMPLIFY) were significantly impacted by the COVID-19 pandemic, as anti-CD20 antibodies increase infection risk. This historical context complicates the interpretation and generalizability of the toxicity data in a post-pandemic era.
The CLL-17 study, comparing continuous ibrutinib to time-limited therapies, showed overlapping efficacy. Its main impact wasn't declaring a winner, but affirming that oncologists can base treatment decisions on patient preference for continuous vs. fixed-duration therapy, knowing outcomes will be similar.
Adding obinutuzumab to acalabrutinib/venetoclax (triplet therapy) deepens responses but led to higher death rates in trials, partly due to COVID-19. This makes it a high-risk, high-reward strategy that experts reserve for younger, healthier patients with high-risk disease who prioritize coming off therapy.